Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

May Shawi

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Journal of Comparative Effectiveness Research|February 10, 2021
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depressionUrvi Desai, Noam Y Kirson, Andrea Guglielmo, et al.
BMJ Open|November 8, 2023
Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomesPeter Nash, Jan P Dutz, Steve Peterson, et al.
Acta Psychiatrica Scandinavica|November 29, 2020
Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depressionIbrahim Turkoz, Larry Alphs, Jaskaran Singh, et al.
Arthritis Research & Therapy|September 15, 2023
Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b studyGeorg Schett, Warner Chen, Sheng Gao, et al.
Rheumatology Advances in Practice|May 20, 2024
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studiesXenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, et al.
Rheumatology and Therapy|September 11, 2024
Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 TrialsJeffrey R Curtis, Atul Deodhar, Enrique R Soriano, et al.
Arthritis Research & Therapy|August 16, 2023
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b studyGeorg Schett, Warner Chen, Sheng Gao, et al.
Annals of the Rheumatic Diseases|November 25, 2021
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)Laura C Coates, Laure Gossec, Elke Theander, et al.
Trials|January 10, 2023
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trialChristopher T Ritchlin, Laura C Coates, Philip J Mease, et al.
Rheumatology and Therapy|October 11, 2023
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 StudyPhilip J Mease, Dafna D Gladman, Denis Poddubnyy, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Journal of Comparative Effectiveness Research|February 10, 2021
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depressionUrvi Desai, Noam Y Kirson, Andrea Guglielmo, et al.
BMJ Open|November 8, 2023
Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomesPeter Nash, Jan P Dutz, Steve Peterson, et al.
Acta Psychiatrica Scandinavica|November 29, 2020
Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depressionIbrahim Turkoz, Larry Alphs, Jaskaran Singh, et al.
Arthritis Research & Therapy|September 15, 2023
Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b studyGeorg Schett, Warner Chen, Sheng Gao, et al.
Rheumatology Advances in Practice|May 20, 2024
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studiesXenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, et al.
Rheumatology and Therapy|September 11, 2024
Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 TrialsJeffrey R Curtis, Atul Deodhar, Enrique R Soriano, et al.
Arthritis Research & Therapy|August 16, 2023
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b studyGeorg Schett, Warner Chen, Sheng Gao, et al.
Annals of the Rheumatic Diseases|November 25, 2021
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)Laura C Coates, Laure Gossec, Elke Theander, et al.
Trials|January 10, 2023
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trialChristopher T Ritchlin, Laura C Coates, Philip J Mease, et al.
Rheumatology and Therapy|October 11, 2023
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 StudyPhilip J Mease, Dafna D Gladman, Denis Poddubnyy, et al.
Pageof 5